MLH1 (%) | PMS2 (%) | MSH2 (%) | MSH6 (%) | MutLα(MLH1/PMS2)(%) | MutSα(MSH2/MSH6) (%) | Tumor type | N | Reference |
---|---|---|---|---|---|---|---|---|
78.2 | 82 | 12.1 | 15.9 | 77.2 | 11.5 | MSI solid tumors | 1057 | [31] |
N/A | N/A | N/A | N/A | 3.7 | 1.8 | GC | 107 | [253] |
N/A | 1.8 | N/A | N/A | 20.4 | 5.3 | CRC | 113 | [254] |
N/A | N/A | 5.9 | 11.8 | 41.2 | N/A | Undifferentiated GIC and PC | 17 | [255] |
30.2 | 34.9 | 55.8 | 46.5 | N/A | N/A | High-grade gliomas | 355 | [256] |
7.1(partially negative) | 7.1(partially negative) | 7.1(partially negative) | 7.1(partially negative) | N/A | N/A | Primary GBM | 57 | [257] |
7.1(partially negative) | 7.1(partially negative),7.1(completely negative) | 14.3(partially negative),7.1(completely negative) | 57.1(partially negative),28.6(completely negative) | N/A | N/A | Recurrent GBM | 57 | [257] |
0.9 | 12.3 | 2.7 | 16.8 | N/A | N/A | Prostate cancer | 220 | [258] |
59.5 | 67.6 | 18.9 | 32.4 | N/A | N/A | Endometrial endometrioid adenocarcinoma | 107 | [259] |
23.8 | N/A | 14.8 | 9.3 | N/A | N/A | Endometrioid endometrial carcinoma | 486 | [260] |
83.34 | 3.33 | 1.37 | 4.11 | N/A | N/A | CRC | 1000 | [261] |
20 | 13.3 | 33.3 | 33.3 | N/A | N/A | CRC,EC | 15 | [262] |
23 | N/A | N/A | N/A | N/A | N/A | pNETs | 48 | [263] |
36 | N/A | 16 | N/A | N/A | N/A | pNETs | 55 | [264] |